New study tracks best ways to treat hemophilia a when standard therapy fails

NCT ID NCT04023019

Recruiting now Knowledge-focused Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study follows 120 men with hemophilia A who have developed inhibitors (antibodies that block standard treatment). Researchers will observe how doctors manage their condition using different therapies, including immune tolerance induction and newer drugs like emicizumab. The goal is to see which approaches work best to lower inhibitor levels and reduce bleeding episodes over up to 5 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors understand which treatment approaches work best for managing hemophilia A with inhibitors, potentially improving care guidelines.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by differences in patient care and treatment choices.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematologic disorder hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMOPHILIA A

Contacts and locations

Locations

Arthur M. Blank Hospital
RECRUITING

Atlanta, Georgia, 30329, United States
HZRM Hämophilie-Zentrum Rhein Main
RECRUITING

Mörfelden-Walldorf, 64546, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.